Skip to main content

RenovoRx, Inc.

corporate_fare Company Profile

RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed RNXT - Latest Insights

RNXT
Apr 27, 2026, 5:20 PM EDT
Filing Type: 424B3
Importance Score:
8
RNXT
Apr 16, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
8
RNXT
Apr 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
RNXT
Mar 30, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
RNXT
Mar 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
RNXT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
RNXT
Mar 24, 2026, 9:16 PM EDT
Filing Type: 4
Importance Score:
7
RNXT
Mar 24, 2026, 9:15 PM EDT
Filing Type: 4
Importance Score:
8
RNXT
Mar 23, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
RNXT
Mar 18, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
RNXT
Feb 27, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
RNXT
Feb 06, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
RNXT
Jan 02, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
9